Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zibotentan + docetaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Zibotentan + docetaxel** is a combination therapy studied in metastatic castration-resistant prostate cancer (mCRPC). Zibotentan (ZD4054) is an oral specific endothelin A receptor antagonist, while docetaxel is a cytotoxic taxane chemotherapeutic agent that stabilizes microtubules and disrupts cell division. The rationale for this combination was based on the hypothesis that targeting both tumor biology (via blockade of endothelin A receptor involved in tumor invasion, angiogenesis, and inhibition of apoptosis) and providing cytotoxic therapy might improve clinical outcomes. Phase I, II, and large phase III clinical trials evaluated efficacy and safety; results demonstrated no significant improvement in overall survival or progression endpoints compared to docetaxel plus placebo. The most commonly reported adverse effects included edema, diarrhea, alopecia, and nausea[1][5].
- Brand names
- Taxotere + zibotentan
- Other names
- zibotentan + docetaxelZD4054 + docetaxelzibotentan and docetaxeldocetaxel and zibotentanTaxotere + zibotentan
02
Targets
TUBB (Tubulin (alpha and beta subunits))EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on zibotentan + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zibotentan + docetaxel.